From bispecific engineering to clinically relevant data sourcing, evolving antibody technologies advance oncology therapeutics.

Researchers at Leipzig University and Martin Luther University Halle-Wittenberg have investigated a previously unknown ...

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy ...

Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...